Sangart is a biopharmaceutical company dedicated to improving transfusion practices worldwide. The company is focused on the research, development, and commercialization of innovative transfusion medicine solutions to the benefit of all people. Based on pre-clinical studies, Sangart's lead product, HemospanTM, appears to fulfill the three fundamental requirements for a successful alternative to blood transfusion: efficacy, safety, and affordability.



View Their Site

__________________
Mr. Jan B. Wade
Blood Management Consultant
Enhance Outcomes - Control Cost
For Information Call - 360 296-1807
Email